+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment effect at different levels of creatinine clearance following eptifibatide in planned coronary stent implantation



Treatment effect at different levels of creatinine clearance following eptifibatide in planned coronary stent implantation



Journal of the American College of Cardiology 37(2 Supplement A): 11A




(PDF emailed within 1 workday: $29.90)

Accession: 035980133

Download citation: RISBibTeXText


Related references

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). American Journal of Cardiology 91(1): 17-21, 2002

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356(9247): 2037-2044, 2001

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled study. Indian Heart Journal 53(3): 376-376, 2001

Effect of Eptifibatide on coronary flow reserve following coronary stent implantation (An ESPRIT substudy). American Journal of Cardiology 87(11): 1293-1295, 2001

In-hospital costs of coronary stent implantation with and without eptifibatide. American Journal of Cardiology 89(1): 61-64, January 1, 2002

Eptifibatide in coronary stent implantation Long-term results of the ESPRIT trial. Circulation 104(17 Supplement): II 94, October 23, 2001

High-dose eptifibatide in elective coronary stent implantation Results of the ESPRIT trial. European Heart Journal 21(Abstract Supplement): 146, August-September, 2000

High-dose eptifibatide in coronary stent implantation 1 Year results of the ESPRIT trial. Journal of the American College of Cardiology 37(2 Supplement A): 76A, 2001

High-dose eptifibatide in coronary stent implantation 6 Month results of the ESPRIT trial. Circulation 102(18 Supplement): II 663, October 31, 2000

Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114(9): 921-928, 2006

Adjunctive therapy with eptifibatide administered as a double bolus plus infusion in a patient undergoing elective implantation of a coronary stent. Journal of Invasive Cardiology 12 Suppl D: 8d-9d, 2001

Primary stenting of occluded native coronary arteries II--rationale and design of the PRISON II study: a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions. American Heart Journal 149(3): E1-E3, 2005

Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: An analysis using propensity score methods. 2007

In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. American Journal of Cardiology 89(1): 61-64, 2002

Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). Eurointervention 7(10): 1189-1196, 2012